These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20861918)

  • 1. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
    Jabbour E; Deininger M; Hochhaus A
    Leukemia; 2011 Feb; 25(2):201-10. PubMed ID: 20861918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Quintás-Cardama A; Cortés JE; Kantarjian H
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
    Steegmann JL; Cervantes F; le Coutre P; Porkka K; Saglio G
    Leuk Lymphoma; 2012 Dec; 53(12):2351-61. PubMed ID: 22616642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
    Jabbour E; Kantarjian HM; Jones D; Reddy N; O'Brien S; Garcia-Manero G; Burger J; Cortes J
    Blood; 2008 Dec; 112(13):4839-42. PubMed ID: 18818391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 9. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
    Pinilla-Ibarz J; Cortes J; Mauro MJ
    Cancer; 2011 Feb; 117(4):688-97. PubMed ID: 20922786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S; Sawyer S
    JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E; Kantarjian H
    Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral BMS-354825 rescues Gleevec-resistant CML.
    Cancer Biol Ther; 2004 Aug; 3(8):700. PubMed ID: 15751154
    [No Abstract]   [Full Text] [Related]  

  • 15. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
    Holstein SA; Stokes JB; Hohl RJ
    Leuk Res; 2009 Feb; 33(2):344-7. PubMed ID: 18835038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
    Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.